（GLP-1，临床II期）的超长半衰期，使其具备每月注射一次的药代动力学基础。而公司SYH2082 是一 款正推进至临床I期的每月一次注射长效GLP1R/GIP激动剂，我们期待有更多优异疗效和安全性数据读 出。 对外授权持续兑现，有望形成常态化收入。2025 年公司已实现口服小分子GLP-1（1.2 亿美元首付 款）、阿斯利康战略合作（1.1亿美元预付款）、伊利替康脂质体（1500 万美元首付款）、ROR1ADC （1500 万美元首付款）的对外授权。公司研发管线中还有EGFR ADC/SiRNA系列等进度领先的创新资 机构：中金公司 研究员：俞波/陈诗雨/张琎 公司近况 石药集团公告与阿斯利康签订研发合作与授权协议。 评论 中国创新药授权出海再获里程碑式突破。根据公告，石药集团及附属公司授权阿斯利康在全球范围内 （除中国内地/港澳台）独家开发、生产和商业化8 个创新长效多肽药物项目（包括SYH2082及3 个临床 前阶段分子，并就另4 个新增项目进行合作），阿斯利康将支付合计12 亿美元预付款以及后续累计最高 35 亿/138 亿美元的开发/销售里程碑款项。其中巨石生物（新诺威控股子公司）有权收取首付款的3 ...

Core Insights - The innovative drug Enoglutide Injection (brand name Xianyida) developed by Hangzhou Xianweida Biotechnology Co., Ltd. has received approval from the National Medical Products Administration, marking a significant milestone for the company and the industry [1] - This drug is aimed at blood sugar control for adult patients with type 2 diabetes and is the first approved innovative drug in Zhejiang Province for 2026, providing a new treatment option for over 100 million diabetes patients globally [1] Company Overview - Xianweida was established in August 2017 and has focused on innovative weight management therapies for obesity and related diseases [1] - Enoglutide is the company's first approved product and represents a breakthrough as the world's first biased GLP-1 (glucagon-like peptide-1) hypoglycemic drug [1] - The biased GLP-1 developed by Xianweida offers a significant upgrade over traditional GLP-1 receptor agonists, achieving better clinical efficacy while maintaining blood sugar control [1] Product Pipeline and Market Position - In addition to type 2 diabetes, Xianweida is targeting indications for overweight/obesity with multiple products in the pipeline, including a submitted application for Enoglutide for obesity in China [2] - The company is developing several oral products and aims to become the "first stock in weight management" by submitting a prospectus to the Hong Kong Stock Exchange in September 2025 [2] - The GLP-1 sector is currently one of the hottest areas in the global biopharmaceutical field, attracting major pharmaceutical companies like Novo Nordisk, Eli Lilly, Pfizer, and AstraZeneca, as well as numerous innovative biotech firms in China [2] Industry Context - The successful approval of the new drug is seen as a significant milestone for Chinese pharmaceutical companies in the field of metabolic diseases [2] - Hangzhou has been promoting rapid development in the biopharmaceutical industry through policy support and ecosystem optimization, with 5 innovative drugs approved in 2025, accounting for 83% of the total in the province [2] - The Hangzhou Medical Port has seen 132 innovative drugs enter clinical trials, with 4 currently in the approval process [2]

Core Insights - The CDMO (Contract Development and Manufacturing Organization) business of multinational companies in China is experiencing significant decline, with many exiting the market entirely [1][8] - The Chinese CDMO market is growing rapidly, with a compound annual growth rate of 39.9% from 2018 to 2023, and is expected to reach 208.4 billion RMB by 2028 [16] Group 1: Multinational CDMO Operations in China - Multinational companies like Lonza, Thermo Fisher, and Merck have faced challenges in their CDMO operations in China, with many either closing facilities or selling them off [4][5][6] - Lonza's Guangzhou factory, which was operational for only three years, was sold to a local company due to insufficient orders [4] - Thermo Fisher's factory in Hangzhou is struggling with low order volumes, and its future remains uncertain [5][6] Group 2: Local CDMO Developments - Zhaoyan Biotech's new manufacturing base in Guangzhou, which focuses on large molecule CDMO, signifies a strategic move to enhance capacity and create a collaborative platform for biopharmaceutical innovation in Southeast Asia [3] - Local companies are increasingly building their own production capabilities, reducing reliance on foreign CDMO services [14] Group 3: Market Dynamics and Trends - The introduction of the MAH (Marketing Authorization Holder) system in 2019 has lowered production barriers, allowing more companies to utilize CDMO services [11] - Despite the advantages of a large workforce and lower costs, foreign CDMOs have struggled to establish a foothold in China due to high pricing models that do not align with local market conditions [12][13] - The efficiency and cost-effectiveness of Chinese CDMOs are becoming competitive with their foreign counterparts, leading to a shift in market dynamics [15][16]

1月30日，石药集团正式宣布与阿斯利康达成研发合作协议。根据协议，石药集团将获得12亿美元的预 付款，并有权获得最高35亿美元的潜在研发里程碑付款、最高138亿美元的潜在销售里程碑付款，以及 基于相关授权产品年净销售额、最高达双位数比例的销售提成。 石药集团的一则合作，创造了两个意想不到的结果。 其中之一是其BD规模之大，超出市场预期。 12亿美元的首付款，仅次于三生制药与辉瑞的合作。 然而，与之形成鲜明反差的是其惨淡的股价表现——当日股价低开低走，最终跌幅达10.2%。这也让投 资者质疑，BD消息是否提前泄露。 无论此次股价暴跌是否与石药集团的保密工作不到位有关，这一现象都清晰指向一个核心结论：医药行 业单纯炒作BD的时代，已经彻底翻篇了。 "翻车"的石药 石药集团翻车了。 从交易规模来看，这无疑是中国创新药历史上最大的交易之一——石药集团与阿斯利康达成的研发合作 协议，潜在总交易额高达185亿美元。 尽管这笔巨额交易中，包含最高35亿美元的研发里程碑付款和最高138亿美元的销售里程碑付款，这类 款项受研发进度、市场销售等不确定因素影响较大，更像是"画饼"，但12亿美元的首付款却是实打实的 收益。 正是凭借 ...

Core Viewpoint - The collaboration between Stone Pharmaceutical Group and AstraZeneca is a significant strategic partnership with a potential total deal value of up to $18.5 billion, highlighting the importance of innovative drug development and technology platforms in the pharmaceutical industry [1][2]. Group 1: Financial Aspects - The initial payment of $1.2 billion is the second-largest upfront payment in recent collaborations, following a $1.25 billion payment from a partnership between Three Life Pharmaceuticals and Pfizer in 2025 [2]. - The deal includes potential milestone payments of up to $3.5 billion for research and up to $13.8 billion for sales, along with a sales commission based on net sales of authorized products [1]. Group 2: Technological and Developmental Focus - The collaboration is centered around Stone Pharmaceutical Group's proprietary sustained-release drug delivery technology platform and AI-driven peptide drug discovery platform, indicating AstraZeneca's interest in the underlying technological capabilities [2]. - The sustained-release technology allows for monthly or longer dosing intervals for peptide drugs, enhancing patient compliance for long-term treatments [2]. - Stone Pharmaceutical Group will collaborate with AstraZeneca on the discovery of innovative peptide molecules and the development of long-acting delivery products, including a weight management product and several other projects in various stages of development [2][3]. Group 3: Historical Context and Market Position - This is not the first collaboration between Stone Pharmaceutical Group and AstraZeneca; the total deal value from their three collaborations has exceeded $25 billion [3]. - AstraZeneca has shown a strong commitment to the Chinese market, ranking first among foreign pharmaceutical companies in sales and actively engaging in patent licensing transactions [3]. - Stone Pharmaceutical Group, established in 1994, is transitioning from generic to innovative drug development, facing challenges with its key products as core patents expire [3][4]. Group 4: R&D Investment and Industry Trends - Stone Pharmaceutical Group has steadily increased its R&D spending from 2 billion yuan in 2019 to 5.19 billion yuan in 2024, reflecting its focus on innovative drug development [4]. - The company has eight innovative technology platforms and aims to launch a billion-yuan peak product annually from these platforms [4]. - The trend in the industry shows a surge in business development transactions, with over 150 deals and a total value exceeding $130 billion in 2025, indicating a robust market for innovative drug collaborations [4].

Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry in China [6] Core Insights - The focus remains on the combination of IO (Immuno-Oncology) and ADC (Antibody-Drug Conjugates), with significant advancements expected in their joint application [10][11] - The year 2026 is identified as a critical year for the combination of IO and ADC, with expectations for increased demand for ADCs, particularly in the context of various cancer treatments [11][41] Summary by Sections Section 1: Focus on Second-Generation IO and ADC - Merck's sac-TMT is a strategic focus, with 16 ongoing Phase III clinical trials, particularly in gynecological cancers [14][15] - AstraZeneca has 8 ADCs in clinical stages, with significant data readouts expected in 2026 [19][20] - Pfizer is advancing 4 Phase III clinical trials for its PD-1/VEGF dual antibody SSGJ-707, highlighting its strategic importance in oncology [26][27] - Johnson & Johnson aims to become the leading oncology company by 2030, focusing on multiple myeloma and various cancers [30] - Bristol-Myers Squibb (BMS) is advancing its PD-L1/VEGF dual antibody and oral CELMoD therapies, with significant data catalysts expected in 2026 [32][33] - Roche is focusing on breast cancer, with its oral SERD Giredestrant expected to be approved soon [37][38] Section 2: The Year of IO+ADC Combination - The combination of IO and ADC is seen as a key development direction, with various clinical trials underway [41] - The first-generation IO+ADC combinations are competitive, with sac-TMT emerging as a significant player [42] - The second-generation IO combined with chemotherapy is led by AK112, with multiple milestones expected in the coming years [47] - The second-generation IO combined with ADC is still in early exploration, with AstraZeneca leading the way [49] Section 3: Investment Recommendations and Targets - The report identifies several investment targets, including Kangfang Biotech, 3SBio, and others, highlighting their potential in the oncology sector [11][56]

Core Viewpoint - Sangamo's significant revenue and profit growth in 2025 is primarily driven by a substantial upfront payment from Pfizer for a licensing agreement, marking a pivotal moment in the company's financial performance [1][3]. Financial Performance - The company forecasts a total revenue of approximately 4.2 billion yuan for 2025, representing an increase of about 3.006 billion yuan, or a growth rate of 251.76% compared to the previous year [1][2]. - The expected net profit attributable to shareholders is around 2.9 billion yuan, an increase of approximately 2.195 billion yuan, reflecting a year-on-year growth of 311.35% [1][2]. - The projected non-GAAP net profit is about 2.8 billion yuan, showing a staggering increase of 1.038 billion yuan, or 1038.21% year-on-year [1][3]. Licensing Agreement with Pfizer - In 2025, the company entered into a licensing agreement with Pfizer for the SSGJ-707 project, receiving an upfront payment of approximately 2.89 billion yuan, which significantly boosted revenue and profit [3][5]. - The total transaction value of the licensing agreement exceeds 6 billion USD, setting a historical record for upfront payments in China's innovative drug sector [4]. Research and Development Investment - The company has invested over 1.7 billion yuan in research and development over the past five years, with R&D expenses for the first three quarters of 2025 amounting to 300 million yuan, representing 26.88% of total revenue [6]. - The company has a diverse pipeline with 22 ongoing projects in the autoimmune field, including several core projects in advanced clinical stages [6].

三生国健表示，报告期内，公司与辉瑞达成重要合作，公司收到辉瑞就707项目支付的授权许可首付款 并相应确认收入约28.9亿元，导致2025年度的营业收入、归属净利润以及扣非净利润均出现较大幅度的 增长。 北京商报讯（记者 丁宁）1月26日晚间，三生国健（688336）发布2025年业绩预告显示，公司2025年预 计实现归属净利润29亿元，同比增加21.95亿元，较上年同期涨幅约311.35%。 ...

Core Insights - The JPMorgan Global Healthcare Conference serves as a significant platform for the biopharmaceutical industry, influencing capital flows and industry dynamics for the year ahead [1] - This year's conference highlighted the increasing presence of Chinese biotech companies, marking a shift from being mere spectators to key players in the global market [2][3] Group 1: Chinese Biotech Companies - Seven Chinese companies, including WuXi AppTec and BeiGene, presented on the main stage, with an additional 17 companies showcasing in the Asia-Pacific session [2] - The transformation of Chinese companies from the periphery to the center of the conference reflects their substantial innovation value, evidenced by numerous licensing deals announced during the event [3] Group 2: Licensing Deals and Collaborations - Notable licensing agreements included a $650 million upfront payment from AbbVie to Rongchang Biopharma for the global rights to its PD-1/VEGF dual-specific antibody, with a total potential deal value of up to $5.6 billion [3] - Other significant collaborations involved Zhongsheng Peptide and Sai Shen Pharmaceutical partnering with Novartis, with the latter's deal valued at approximately $1.665 billion [3] Group 3: MNCs and Market Dynamics - The cautious approach of multinational corporations (MNCs) towards acquisitions is driven by the impending "patent cliff," with over $320 billion in market potential products set to lose patent protection in the next decade [3][5] - MNCs are increasingly favoring "asset-based acquisitions" over full company buyouts, allowing them to efficiently acquire core assets without the burdens of integrating entire companies [4] Group 4: AI in Drug Development - AI's integration into drug development emerged as a central theme, with Eli Lilly and NVIDIA announcing a partnership to establish a $1 billion AI innovation lab aimed at addressing long-standing challenges in the pharmaceutical industry [5][6] - The acquisition of Modella AI by AstraZeneca further emphasizes the growing importance of AI in enhancing drug discovery and clinical development processes [6] Group 5: Future Outlook - The 2026 JPM conference is expected to reflect a new paradigm where Chinese innovation becomes essential, and AI evolves from a supportive tool to a foundational infrastructure in drug development [8][9]

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in their stock prices over the next 12 months [29]. Core Insights - The MSCI China Healthcare Index has increased by 9.2% since the beginning of 2026, outperforming the MSCI China Index, which rose by 5.6% [1]. - The pharmaceutical industry has seen significant growth, driven by strong institutional investor interest and the ongoing trend of innovative drugs going global [1]. - The report emphasizes the importance of clinical progress and data validation for pipelines that have already gone overseas, suggesting that this trend will continue in the long term [1]. Summary by Sections Industry Overview - The report highlights a robust trend in the outbound licensing of innovative drugs, with multiple business development (BD) transactions occurring at the start of 2026, reflecting a high level of activity in the sector [4]. - Key transactions include significant upfront and milestone payments for various drugs, indicating strong market interest and potential for future growth [4]. Company Ratings and Valuations - The report provides detailed valuations for several companies, including: - **Sangfor Technologies (1530 HK)**: Market cap of $7,598.4 million, target price of $37.58, with a 54% upside potential [2]. - **Gusongtang (2273 HK)**: Market cap of $963.3 million, target price of $44.95, with a 46% upside potential [2]. - **WuXi AppTec (2268 HK)**: Market cap of $10,551.0 million, target price of $88.00, with a 28% upside potential [2]. - **China National Pharmaceutical Group (1177 HK)**: Market cap of $15,951.4 million, target price of $9.40, with a 42% upside potential [2]. Market Trends - The report notes that the competition in the PD-(L)1/VEGF space is intensifying, with several companies advancing their clinical trials and aiming for first-line indications [4]. - The report suggests that the efficiency and breadth of clinical trials, as well as the richness of combination therapies, will be critical factors in determining success in this competitive landscape [4].